• Publications
  • Influence
Killing of autologous B-lineage malignancy using CD3 x CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma.
TLDR
Various types of experiments showed that efficient CD3 x CD19 BsAb-mediated cytolytic capacity was not dependent on expression of either of these surface proteins, which contrasts with normal major histocompatibility complex-restricted antigen-specific cytotoxicity and may be essential for effective in vivo application of this Bs Ab. Expand
Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
TLDR
Two bispecific monoclonal antibodies with functionally different Fc domains represent alternative strategies in BsAb therapy, the efficacy of which deserves to be compared in vivo. Expand
Killing of Autologous B-Lineage Malignancy Using CD3 x CD19 Bispecific Monoclonal Antibody in End Stage Leukemia and Lymphoma
TLDR
Various types of experiments showed that efficient CD3 x CD19 BsAb-mediated cytolytic capacity was not dependent on expression of either of these surface proteins, which contrasts with normal major histocompatibility complex-restricted antigen-specific cytotoxicity and may be essential for effective in vivo application of this Bs Ab. Expand
The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
TLDR
This clonogenic assay shows the importance of repeated administration of CD3 x CD19 BsAb and IL-2 and offers the possibility to compare it with other therapies in B-cell malignancy and shows the number of T cells proved critical in lysis of ALL-B cells. Expand
Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19)
TLDR
Results show that fresh humanLeukaemia/lymphoma cells, freshly derived from active lymphoblastic leukaemia as well as non‐Hodgkin's lymphoma (NHL) patients, can be effectively killed in the presence of this BsAb by activated T cells. Expand
Interaction of human monocyte Fc gamma receptors with rat IgG2b. A new indicator for the Fc gamma RIIa (R-H131) polymorphism.
TLDR
A unique reactivity pattern for rat IgG2b Abs is found, interacting both with the high affinity Fc Gamma RIa in all donors and Fc gamma RIIa of individuals expressing the IIa-H131 allotype. Expand
Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic
We previously reported that a CD3×CD19 bispecific antibody (bsAb) can induce efficient killing of tumour cells by preactivated T cells isolated from patients with B cell malignancy. For futureExpand
Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (alpha CD3/alpha CD19).
TLDR
Results show that fresh humanLeukaemia/lymphoma cells, freshly derived from active lymphoblastic leukaemia (ALL) as well as non-Hodgkin's lymphoma (NHL) patients, can be effectively killed in the presence of this BsAb by activated T cells. Expand
The Efficacy of CD 3 x CD 19 Bispecific Monoclonal Antibody ( BsAb ) in a Clonogenic Assay : The Effect of Repeated Addition of BsAb and Interleukin-2
To evaluate the potency by which human T cells are targeted and activated by bispecific monoclonal antibodies (BsAbs) t o lyse tumor cells, a clonogenic assay was developed. The efficacy of aExpand